|
1
|
DeSantis CE, Ma J, Gaudet MM, Newman LA,
Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer
statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Viedma-Rodríguez R, Baiza-Gutman L,
Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz
Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D:
Mechanisms associated with resistance to tamoxifen in estrogen
receptor-positive breast cancer (review). Oncol Rep. 32:3–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaufmann M, Jonat W, Hilfrich J, Eidtmann
H, Gademann G, Zuna I and von Minckwitz G: Improved overall
survival in postmenopausal women with early breast cancer after
anastrozole initiated after treatment with tamoxifen compared with
continued tamoxifen: The ARNO 95 study. J Clin Oncol. 25:2664–2670.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clemons M, Danson S and Howell A:
Tamoxifen (‘Nolvadex’): A review. Cancer Treat Rev. 28:165–180.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davies C, Godwin J, Gray R, Clarke M,
Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al:
Relevance of breast cancer hormone receptors and other factors to
the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu L, Liu S, Luo H, Chen C, Zhang X, He L
and Tu G: GPR30-mediated HMGB1 upregulation in CAFs induces
autophagy and tamoxifen resistance in ERalpha-positive breast
cancer cells. Aging (Albany NY). 13:16178–16197. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Gong X and Zhang Y: Network-based
approach to identify prognosis-related genes in tamoxifen-treated
patients with estrogen receptor-positive breast cancer. Biosci Rep.
41:BSR202030202021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan W, Chang J and Fu P: Endocrine therapy
resistance in breast cancer: Current status, possible mechanisms
and overcoming strategies. Future Med Chem. 7:1511–1519. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dittmer J: Nuclear mechanisms involved in
endocrine resistance. Front Oncol. 11:7365972021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arpino G, De Angelis C, Giuliano M,
Giordano A, Falato C, De Laurentiis M and De Placido S: Molecular
mechanism and clinical implications of endocrine therapy resistance
in breast cancer. Oncology. 77 (Suppl 1):23–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsubaki M, Komai M, Fujimoto S, Itoh T,
Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, et
al: Activation of NF-κB by the RANKL/RANK system up-regulates snail
and twist expressions and induces epithelial-to-mesenchymal
transition in mammary tumor cell lines. J Exp Clin Cancer Res.
32:622013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saitoh M: Involvement of partial EMT in
cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Derynck R and Weinberg RA: EMT and cancer:
More than meets the eye. Dev Cell. 49:313–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ribatti D, Tamma R and Annese T:
Epithelial-mesenchymal transition in cancer: A historical overview.
Transl Oncol. 13:1007732020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei Z, Shan Z and Shaikh ZA:
Epithelial-mesenchymal transition in breast epithelial cells
treated with cadmium and the role of snail. Toxicol Appl Pharmacol.
344:46–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Davis FM, Stewart TA, Thompson EW and
Monteith GR: Targeting EMT in cancer: Opportunities for
pharmacological intervention. Trends Pharmacol Sci. 35:479–488.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baranwal S and Alahari SK: Molecular
mechanisms controlling E-cadherin expression in breast cancer.
Biochem Biophys Res Commun. 384:6–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mariotti A, Perotti A, Sessa C and Rüegg
C: N-cadherin as a therapeutic target in cancer. Expert Opin
Investig Drugs. 16:451–465. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li
J and Zhang Q: Resveratrol reverses Doxorubicin resistance by
inhibiting epithelial-mesenchymal transition (EMT) through
modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin
Cancer Res. 36:192017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Q, Gun M and Hong XY: Induced
tamoxifen resistance is mediated by increased methylation of
e-cadherin in estrogen receptor-expressing breast cancer cells. Sci
Rep. 9:141402019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Liu G, Kang Y, Dong Z, Qian Q and
Ma X: N-cadherin expression is associated with acquisition of EMT
phenotype and with enhanced invasion in erlotinib-resistant lung
cancer cell lines. PLoS One. 8:e576922013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Işeri OD, Kars MD, Arpaci F, Atalay C, Pak
I and Gündüz U: Drug resistant MCF-7 cells exhibit
epithelial-mesenchymal transition gene expression pattern. Biomed
Pharmacother. 65:40–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim MR, Choi HK, Cho KB, Kim HS and Kang
KW: Involvement of Pin1 induction in epithelial-mesenchymal
transition of tamoxifen-resistant breast cancer cells. Cancer Sci.
100:1834–1841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Nes JG, de Kruijf EM, Putter H,
Faratian D, Munro A, Campbell F, Smit VT, Liefers GJ, Kuppen PJ,
van de Velde CJ and Bartlett JM: Co-expression of SNAIL and TWIST
determines prognosis in estrogen receptor-positive early breast
cancer patients. Breast Cancer Res Treat. 133:49–59. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The e-cadherin and
n-cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications, and challenges. Cells.
8:11182019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gooding AJ and Schiemann WP:
Epithelial-mesenchymal transition programs and cancer stem cell
phenotypes: Mediators of breast cancer therapy resistance. Mol
Cancer Res. 18:1257–1270. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luqmani YA and Alam-Eldin N: Overcoming
resistance to endocrine therapy in breast cancer: New approaches to
a nagging problem. Med Princ Pract. 25 (Suppl 2):28–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alves CL, Elias D, Lyng MB, Bak M and
Ditzel HJ: SNAI2 upregulation is associated with an aggressive
phenotype in fulvestrant-resistant breast cancer cells and is an
indicator of poor response to endocrine therapy in estrogen
receptor-positive metastatic breast cancer. Breast Cancer Res.
20:602018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Butti R, Das S, Gunasekaran VP, Yadav AS,
Kumar D and Kundu GC: Receptor tyrosine kinases (RTKs) in breast
cancer: Signaling, therapeutic implications and challenges. Mol
Cancer. 17:342018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen X, Gu J, Neuwald AF, Hilakivi-Clarke
L, Clarke R and Xuan J: Identifying intracellular signaling modules
and exploring pathways associated with breast cancer recurrence.
Sci Rep. 11:3852021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yao J, Deng K, Huang J, Zeng R and Zuo J:
Progress in the understanding of the mechanism of tamoxifen
resistance in breast cancer. Front Pharmacol. 11:5929122020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hiscox S, Jiang WG, Obermeier K, Taylor K,
Morgan L, Burmi R, Barrow D and Nicholson RI: Tamoxifen resistance
in MCF7 cells promotes EMT-like behaviour and involves modulation
of beta-catenin phosphorylation. Int J Cancer. 118:290–301. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Q, Cheng Y, Wang Y, Fan Y, Li C,
Zhang Y, Wang Y, Dong Q, Ma Y, Teng YE, et al: Tamoxifen reverses
epithelial-mesenchymal transition by demethylating miR-200c in
triple-negative breast cancer cells. BMC Cancer. 17:4922017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:9652016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and García De Herreros A: The transcription
factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Peinado H, Marin F, Cubillo E, Stark HJ,
Fusenig N, Nieto MA and Cano A: Snail and E47 repressors of
E-cadherin induce distinct invasive and angiogenic properties in
vivo. J Cell Sci. 117:2827–2839. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Blanco MJ, Moreno-Bueno G, Sarrio D,
Locascio A, Cano A, Palacios J and Nieto MA: Correlation of Snail
expression with histological grade and lymph node status in breast
carcinomas. Oncogene. 21:3241–3246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee YM, Park T, Schulz RA and Kim Y:
Twist-mediated activation of the NK-4 homeobox gene in the visceral
mesoderm of Drosophila requires two distinct clusters of E-box
regulatory elements. J Biol Chem. 272:17531–17541. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng MY, Wang K, Song HT, Yu HW, Qin Y,
Shi QT and Geng JS: Metastasis-induction and apoptosis-protection
by TWIST in gastric cancer cells. Clin Exp Metastasis.
26:1013–1023. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan
XY, Chua CW, Leung SC, Na Y and Wang X: Significance of TWIST
expression and its association with E-cadherin in bladder cancer.
Hum Pathol. 38:598–606. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu Y, Xu Y, Liao L, Zhou N, Theissen SM,
Liao XH, Nguyen H, Ludwig T, Qin L, Martinez JD, et al: Inducible
knockout of Twist1 in young and adult mice prolongs hair growth
cycle and has mild effects on general health, supporting Twist1 as
a preferential cancer target. Am J Pathol. 183:1281–1292. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY,
Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, et al: Bmi1 is
essential in Twist1-induced epithelial-mesenchymal transition. Nat
Cell Biol. 12:982–992. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Alexander NR, Tran NL, Rekapally H,
Summers CE, Glackin C and Heimark RL: N-cadherin gene expression in
prostate carcinoma is modulated by integrin-dependent nuclear
translocation of Twist1. Cancer Res. 66:3365–3369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang Y, Liu J, Ying X, Lin PC and Zhou BP:
Twist-mediated epithelial-mesenchymal transition promotes breast
tumor cell invasion via inhibition of hippo pathway. Sci Rep.
6:246062016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Casaletto JB and McClatchey AI: Spatial
regulation of receptor tyrosine kinases in development and cancer.
Nat Rev Cancer. 12:387–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: Targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ueno NT and Zhang D: Targeting EGFR in
triple negative breast cancer. J Cancer. 2:324–328. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Normanno N, De Luca A, Maiello MR, Mancino
M, D'Antonio A, Macaluso M, Caponigro F and Giordano A: Epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors in breast
cancer: Current status and future development. Front Biosci.
10:2611–2617. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
60
|
Drury SC, Detre S, Leary A, Salter J,
Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z,
Habben K, et al: Changes in breast cancer biomarkers in the
IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen
treatment. Endocr Relat Cancer. 18:565–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei
Y, Abbruzzese JL, Hortobagyi GN and Hung MC: Epidermal growth
factor receptor cooperates with signal transducer and activator of
transcription 3 to induce epithelial-mesenchymal transition in
cancer cells via up-regulation of TWIST gene expression. Cancer
Res. 67:9066–9076. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lee MY, Chou CY, Tang MJ and Shen MR:
Epithelial-mesenchymal transition in cervical cancer: Correlation
with tumor progression, epidermal growth factor receptor
overexpression, and snail up-regulation. Clin Cancer Res.
14:4743–4750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu H, Zhang HW, Sun XF, Guo XH, He YN,
Cui SD and Fan QX: Tamoxifen-resistant breast cancer cells possess
cancer stem-like cell properties. Chin Med J (Engl). 126:3030–3034.
2013.PubMed/NCBI
|
|
64
|
Johansson HJ, Sanchez BC, Forshed J, Stål
O, Fohlin H, Lewensohn R, Hall P, Bergh J, Lehtiö J and Linderholm
BK: Proteomics profiling identify CAPS as a potential predictive
marker of tamoxifen resistance in estrogen receptor positive breast
cancer. Clin Proteomics. 12:82015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sakunrangsit N, Kalpongnukul N, Pisitkun T
and Ketchart W: Plumbagin enhances tamoxifen sensitivity and
inhibits tumor invasion in endocrine resistant breast cancer
through EMT regulation. Phytother Res. 30:1968–1977. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gutteridge E, Agrawal A, Nicholson R,
Cheung KL, Robertson J and Gee J: The effects of gefitinib in
tamoxifen-resistant and hormone-insensitive breast cancer: A phase
II study. Int J Cancer. 126:1806–1816. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang Y, Zhao X, Xiao Q, Liu Q, Ding K, Yu
F, Zhang R, Zhu T and Ge G: Snail and slug mediate tamoxifen
resistance in breast cancer cells through activation of EGFR-ERK
independent of epithelial-mesenchymal transition. J Mol Cell Biol.
6:352–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
